Plain Language Summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma.
Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S.
Rodriguez-Otero P, et al. Among authors: patel k.
Future Oncol. 2024 Apr 23. doi: 10.2217/fon-2023-0954. Online ahead of print.
Future Oncol. 2024.
PMID: 38651976
Review.